Kirsten Bleckmann

<i>IKZF1</i>^plusDefines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Martin Stanulla, Elif Dağdan, Markéta Žaliová et al. · Journal of Clinical Oncology · 2018 · 285 citations

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

Lenka Hovorková, Markéta Žaliová, Nicola C. Venn et al. · Blood · 2017 · 128 citations · Full text

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

Ondřej Hrušák, Válerie de Haas, Jitka Stančíková et al. · Blood · 2018 · 107 citations · Full text

Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)

Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann et al. · Journal of Clinical Oncology · 2017 · 95 citations

Mixed-phenotype Acute Leukemia, Purpose Delayed Intensification, Pharmacotherapy +21

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

Giovanni Cazzaniga, Paola De Lorenzo, Julia Alten et al. · Haematologica · 2017 · 89 citations · Full text